Priya Shete, MD, MPH

Assistant Adjunct Professor

Priya Shete, MD is a pulmonary and critical care physician at UCSF who is focused on improving access to quality tuberculosis (TB) care for vulnerable populations globally and domestically. Her research and policy portfolio leverages methods in implementation science, social epidemiology, modeling, and health economics to describe patient-centered and health system-derived barriers to TB care.
Understanding the broad social, economic, and structural context in which TB patients interact with low-resourced health systems allows for the development of holistic, multi-sectoral interventions to improve patient and public health outcomes. Dr. Shete completed a degree in Biophysics from Johns Hopkins University and a received her M.D. from Yale, where she focused on the intersection between infectious disease and development for her thesis. She completed her internal medicine training and pulmonary and critical care fellowship training at UCSF. Her research experience is complemented by policy and program perspective gained while working at the Global TB Programme of the World Health Organization and the US Agency for International Development. Dr. Shete sees patients while attending on the Pulmonary Consult Service, in the Medical Intensive Care Unit, and in the Department of Public Health Tuberculosis Clinic at Zuckerberg San Francisco General Hospital.
Certificate, 01/2019 - Implementation Science, University of California
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
MPH, 12/2018 - Health Policy and Management, University of California
06/2015 - Pulmonary and Critical Care Medicine Fellowship, University of California
06/2010 - Residency in Internal Medicine, University of California
M.D., 05/2007 - Medicine, Yale University School of Medicine
B.A., 05/2001 - Biophysics, Johns Hopkins University
  1. Estimated Population-level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.
  2. Use of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice Guide.
  3. Estimating the yield of tuberculosis from key populations to inform targeted interventions in South Africa: a scoping review.
  4. Modeling the Impact of Recommendations for Primary Care-Based Screening for Latent Tuberculosis Infection in California.
  5. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.
  6. Management and Outcomes of Critically-Ill Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series.
  7. Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB).
  8. The University of California San Francisco (UCSF) Training Program in Implementation Science: Program Experiences and Outcomes.
  9. Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective.
  10. Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
  11. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda.
  12. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda.
  13. Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation.
  14. Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda.
  15. Introducing risk inequality metrics in tuberculosis policy development.
  16. Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening.
  17. Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up.
  18. Outlook for tuberculosis elimination in California: An individual-based stochastic model.
  19. Building a tuberculosis-free world: The Lancet Commission on tuberculosis.
  20. Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis.
  21. Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates.
  22. Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study.
  23. Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease.
  24. Defining a migrant-inclusive tuberculosis research agenda to end TB.
  25. Modelling the impact of social protection on tuberculosis: the S-PROTECT project.
  26. Patterns of usage and preferences of users for tuberculosis-related text messages and voice calls in Uganda.
  27. Measuring success: The challenge of social protection in helping eliminate tuberculosis.
  28. Harnessing the Power of Data to Guide Local Action and End Tuberculosis.
  29. Feasibility of a streamlined tuberculosis diagnosis and treatment initiation strategy.
  30. Pathways and costs of care for patients with tuberculosis symptoms in rural Uganda.
  31. Quality of tuberculosis care in India: a systematic review.
  32. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
  33. A unique subpopulation of Tbr1-expressing deep layer neurons in the developing cerebral cortex.
  34. Erratum to “A unique subpopulation of Tbr1-expressing deep layer neurons in the developing cerebral cortex” [Mol. Cell. Neurosci. 30 (2005) 538–551].
  35. A unique subpopulation of Tbr1-expressing deep layer neurons in the developing cerebral cortex.
  36. Physician knowledge of catch-up regimens and contraindications for childhood immunizations.
  37. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis.
  38. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
  39. Real versus theoretical: assessing the risks and benefits of postponing the hepatitis B vaccine birth dose.